This series of patients with milder phenotypes demonstrates the relevance of testing the c.859G>C variant in all SMA patients, with special consideration in cases with two or three SMN2 copies in the context of neonatal screening. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.